Article Summary
于茜 刘宏斌 肖湖南 孙美珠 原晓燕.中性粒细胞与淋巴细胞比值和冠心病的关系[J].现代生物医学进展英文版,2016,16(11):2168-2171.
中性粒细胞与淋巴细胞比值和冠心病的关系
The Relationship between Neutrophil-to-lymphocyte Ratio and CoronaryHeart Disease
  
DOI:
中文关键词: 中性粒细胞/淋巴细胞比值  动脉粥样硬化  冠心病
英文关键词: Neutrophil-to-lymphocyte ratio  Atherosclerosis  Coronary heart disease
基金项目:北京市自然科学基金项目(11BJZ19)
Author NameAffiliation
于茜 刘宏斌 肖湖南 孙美珠 原晓燕 解放军总医院南楼心血管内科解放军总后勤部恩济庄干休所解放军总医院普通外科 
Hits: 850
Download times: 0
中文摘要:
      炎性作用在心血管疾病中的作用越来越重要,尤其是炎性标记物与冠心病之间的相互作用及关系,近年来被广泛研究,大 多研究结果呈现一致性。中性粒细胞与淋巴细胞比值是近些年新兴的炎症标记物,其简易、普及、易获取的特点受到了广泛学者 的肯定。NLR 与动脉粥样硬化相关,相关研究显示动脉僵硬度、钙化积分与NLR 密切相关,另外,高NLR 者更易发现易损斑块。 NLR 可预测急性冠脉综合征的短期及长期心血管事件发生率及死亡率,以及预测稳定性心绞痛预后情况及侧支循环是否丰富。 在冠脉造影的应用中,发现NLR 不仅与冠脉病变严重程度密切相关,能预测完全闭塞病变的发生,及预测无复流的发生。在已有 心血管危险因素的基础上,NLR 可作为新成员,为冠心病的发现及其预后的风险评价提供依据。
英文摘要:
      Inflammatory function has a increasing important role in cardiovascular disease, especially the interaction and relationship between inflammatory markers and coronary heart disease, which is widely studied in recent years and most research results present consistent. Neutrophil-to-lymphocyte ratio is an emerging inflammatory marker in recent years, characterized by inexpensive, easy to obtain, widely available and received by the broad scholars. NLR associated with atherosclerosis, related studies show that arterial stiffness and calcification score strongly linked with NLR. In addition, people with high NLR are susceptible to vulnerable plaque. NLR may predict the short-term and long-termincidence of cardiovascular events and mortality of acute coronary syndrome, as well as prognosis of chronic stable angina and whether collateral circulation is rich. In the application of coronary angiography, NLR was found closely related to the severity of coronary lesions, may also predict the occurrence of chronic coronary total occlusions and no reflow. On the basis of cardiovascular risk factors have been established, NLR can be a new member, providing the basis for the risk evaluation of coronary heart disease and its prognosis.
View Full Text   View/Add Comment  Download reader
Close